Future Market Insights has announced the addition of the "Dilated Cardiomyopathy Market: Global Industry Analysis and Opportunity Assessment 2017-2027" report to their offering
Valley Cottage, NY -- (SBWIRE) -- 07/11/2019 -- Dilated cardiomyopathy is condition caused due to enlargement of left ventricle in the heart. In this state left ventricle gets enlarged, and the heart walls become thinner to pump blood from heart to other body parts of the body. Dilated cardiomyopathy can be developed at any age however it is more common in the people age between 20 to 60 years. In some cases, right ventricle also might be affected due to myopathy. Dilated cardiomyopathy is often caused by genetic mutations and non-genetic conditions like exposure to toxins, autoimmune diseases, heart valve abnormalities and diabetes disease conditions. However, there was no drug approved by FDA to treat dilated cardiomyopathy conditions. Companies are actively working on to develop molecules to treat dilated cardiomyopathy conditions. Array BioPharma carrying out Phase 2 clinical trial for ARRY-797 that inhibits p38 mitogen-activated kinase inhibitor to treat dilated cardiomyopathy. In December 2015, U.S. FDA gave Orphan drug status to the Vasomera (PB1046) molecule developed by PhaseBio Pharmaceuticals that is used treat X-linked dilated cardiomyopathy conditions. Vericel Corporation working on innovative concept to treat dilated cardiomyopathy conditions. Company has developed Ixmyelocel-T, multicellular therapy to treat dilated cardiomyopathy.
Dilated Cardiomyopathy Market: Drivers and Restraints
Globally increase in incidences of congestive heart failure conditions which is leading cause of dilated cardiomyopathy conditions. According to American Heart Association, around 5.3 million Americans have congestive heart failure within an incidence of 660,000 cases diagnosed yearly this signifies potential of the market. The major restraints for the market lack of proper drugs, increase in usage of defibrillators and pacemakers are effecting growth of this market.
Download Market Shares of Leading Players@ https://www.futuremarketinsights.com/reports/sample/rep-gb-2830
Dilated Cardiomyopathy Market: Segmentation
The global Dilated Cardiomyopathy Market is classified on the basis of drug class, distribution channel and geography.
Based on drug class, the dilated cardiomyopathy market is segmented into the following:
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers
Blood thinning medications
Based on distribution channel, the dilated cardiomyopathy market is segmented into the following:
Mail order Pharmacies
Dilated Cardiomyopathy Market: Overview
Normally to treat dilated cardiomyopathy conditions, physicians use the drugs that can treat for congestive heart failure conditions this is due to lack of drugs for dilated cardiomyopathy conditions. Angiotensin receptor blockers occupy the major market share followed by beta blockers by beta blockers. In case of distribution channel, retail pharmacies hold the major market share followed by hospital pharmacies due to easy availability of drugs.
Dilated Cardiomyopathy Market: Regional Overview
Dilated Cardiomyopathy Market is classified into seven regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America occupies the significant market share in dilated cardiomyopathy market. Due to high incidence rates of congestive heart failures in the region. Next to North America, Europe holds the second leading market share for dilated cardiomyopathy conditions. According to European Federation of Pharmaceutical Industries and Associations, over 6000,000 are admitted to hospital, and 55,000 deaths are caused due to the congestive heart failure conditions in Europe. However, APEJ market is expected to grow over the forecast due to increase in awareness and increasing demand for generic drugs are responsible for growth of the market over the forecast period.
Dilated Cardiomyopathy Market: Players
Some of the players in the dilated cardiomyopathy Pfizer Inc., Array BioPharma, Vericel Corporation,PhaseBio Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc, Johnson and Johnson, Merck & Co., Inc, Teva Pharmaceuticals, Astrazeneca plc and Sanofi
The report covers exhaustive analysis on:
Supply & Demand
Competition & Companies involved
Regional analysis includes
North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
The Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)
The report is a compilation of first-hand information, qualitative, and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Download Segment-wise Analysis@ https://www.futuremarketinsights.com/askus/rep-gb-2830
Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current, and projected market size in terms of volume and value
Recent industry trends and developments
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint